Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
Work
Year: 2013
Type: article
Abstract: To design rational therapies for JAK2-driven hematological malignancies, we functionally dissected the key survival pathways downstream of hyperactive JAK2. In tumors driven by mutant JAK2, Stat1, Sta... more
Source: Cell Reports
Institutions Peter MacCallum Cancer Centre, Centre National de la Recherche Scientifique, Institut Curie, Children's Cancer Institute Australia, UNSW Sydney +7 more
Cites: 45
Cited by: 125
Related to: 10
FWCI: 3.733
Citation percentile (by year/subfield): 92.98
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $5,200